Generic Tofacitinib-A More Affordable JAK Inhibitor.
暂无分享，去创建一个
[1] L. Ji,et al. Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis. , 2024, Mayo Clinic proceedings.
[2] M. D. de Wit,et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision , 2022, Annals of the Rheumatic Diseases.
[3] Stanley B. Cohen,et al. Oral surveillance and JAK inhibitor safety: the theory of relativity , 2022, Nature Reviews Rheumatology.
[4] Deepak L. Bhatt,et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. , 2022, The New England journal of medicine.
[5] T. Kvien,et al. New-generation JAK inhibitors: how selective can they be? , 2018, The Lancet.
[6] D. M. van der Heijde,et al. supplement to: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. , 2017 .
[7] I. McInnes,et al. Rheumatoid arthritis , 2016, The Lancet.